

HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Xyrem-Xywav

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:		
HPP Member Number:		Fax:	Phone:	
		Office Contact:		
Date of Birth:			DA DDOMISA ID:	
Patient Primary Phone:		NPI:	PA PROMISe ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Line of Business: ☐ Medicaid ☐ CHIP		Specialty Pharmacy (if applicable):		
Drug Name:		Strength: Refills:		
Quantity: Directions:		Reillis:		
Diagnosis Code:				
HPP's maximum approval time is 12 months but may be less depending on the drug.				
Please attach any pertinent medical history including labs and information for this member that may support approval.				
Please answer the following questions and sign.				
Q1. Is this a renewal?				
Yes	□ No			
Q2. Is the prescriber a neurologist or sleep specialist?				
☐ Yes ☐ No				
Q3. Is the patient 7 years old or older?				
☐ Yes ☐ No				
Q4. Does the patient have a diagnosis of narcolepsy?				
☐ Yes		□ No		
Q5. Does the patient have a diagnosis of idiopathic hypersomnia?				
Yes		☐ No		
Q6. Has the patient tried and failed or is intolerant to treatment with modafinil or armodafinil?				
☐ Yes ☐ No				
Q7. Does the patient have episodes of cataplexy and/or excessive daytime sleepiness?				
☐ Yes				
Q8. For cataplexy, for patients under 18 years old, has the patient tried and failed or is intolerant to treatment with venlafaxine, a tricyclic antidepressant, or an SSRI?				

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Xyrem-Xywav

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q9. For cataplexy, for patients 18 years and older, has the patient tried and failed or is intolerant to treatment with both Wakix and an antidepressant (SNRI, SSRI, or TCA)?		
☐ Yes	□ No	
Q10. For daytime sleepiness, for patients under 18 years old, has the patient tried and failed or is intolerant to treatment with Armodafinil or Modafinil?		
☐ Yes	□ No	
Q11. For daytime sleepiness, for patients 18 years and older, has the patient tried and failed or is intolerant to treatment with all of the following: a) armodafinil or modafinil, b) Sunosi, c) Wakix?		
Yes	□ No	
Q12. Is the patient currently taking a sedative hypnotic or CNS depressant?		
☐ Yes	□ No	
Q13. Was a urine drug screen completed (include most recent date) and consistent with prescribed medications and negative for non-prescribed controlled and illicit substances?		
☐ Yes	☐ No	
Q14. Has the provider checked the PDMP (Pennsylvania Prescription Drug Monitoring Program) before prescribing the medication?		
☐ Yes	□ No	
Q15. Is the patient and prescriber enrolled in the Xyrem/Xywav REMS Program?		
☐ Yes	☐ No	
Q16. For narcolepsy with cataplexy, is there documentation of reduction of frequency of cataplexy attacks?		
☐ Yes	□ No	
Q17. For narcolepsy with EDS or idiopathic hypersomnia, is there documentation of reduction in excessive daytime sleepiness?		
☐ Yes	□ No	
Q18. Has the provider checked the PDMP (Pennsylvania Prescription Drug Monitoring Program) before prescribing the medication?		
☐ Yes	□ No	
Q19. Additional Information:		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Xyrem-Xywav

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	 Date

Updated for 2023